Rapamycin (Sirolimus)

Licensed by Pfizer Catalog No.S1039 Synonyms: AY 22989,NSC-2260804

Rapamycin (Sirolimus) Chemical Structure

Molecular Weight(MW): 914.18

Rapamycin (Sirolimus) is a specific mTOR inhibitor with IC50 of ~0.1 nM HEK293 cells.

Size Price Stock Quantity  
In DMSO USD 306 In stock
USD 70 In stock
USD 270 In stock
USD 670 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 63 Publications

12 Customer Reviews

  • Protein blots showing MYC expression in naive and persister cells after 3 d of treatment with 2 uM AKT inhibitor MK-2206 (AKTi) or 10 nM mTOR inhibitor rapamycin (Rapa).

    Nat Genet 2014 46(4), 364-70. Rapamycin (Sirolimus) purchased from Selleck.

    Cooperative Effects of AR and mTOR Inhibition In Vitro and In Vivo (A) In vitro response of Pten null;Ar+ murine (CaP8) and human (LNCaP) prostate cancer cells to AR knockdown (sh-AR) or pharmacological inhibition of AR (MDV3100, 10 nM) with and without rapamycin (R: 1 nM) treatment (Sc, control sh oligo). (B and D) In vivo response to treatments with castration, MDV3100, rapamycin, or their combinations as measured by cell proliferation (Ki67+cells) and (C and D) tumor burden in Pb-Cre+;-PtenL/L and Pb-Cre+;PtenL/L:ArL/Y mutants. Scale bars represent 2 mm (C), 200 mm (D), and 75 mm (D, inset). Error bars represent mean ±SD.

    Cancer Cell 2011 19(6), 792-804. Rapamycin (Sirolimus) purchased from Selleck.

  • 48 hours after addition of rapamycin(150 nM), the cells were imaged as described in Figure A to detect formation of punctuated GFP-LC3 structure. Quantification represented the ratio of GFP-LC3 punctuated positive cell to the total cell counted(Figure B).

    Cell Res 2012 22(6), 1003-21. Rapamycin (Sirolimus) purchased from Selleck.

    H4-LC3-GFP cells were treated with 1 nM IFNA2 for the indicated periods in the presence of 200 nM rapamycin. Images of the cells were collected using an ArrayScan HCS 4.0 Reader. Representative cells are shown. The average spot intensity in 500 cells from each indicated sample was determined. Data are displayed as means ?SD of the spot intensity per cell (below). RLU, relative leight unit.

    Autophagy 2015 11(4), 617-28. Rapamycin (Sirolimus) purchased from Selleck.

  • Rheb Induces Phospho-eIF2a Independent of mTORC1 and Promotes Phospho-eIF2a Predominantly through PERK (A) Western blotting of indicated proteins of HEK293 expressing cDNAs of myc (control) or myc-Rheb WT were grown in DMEM with serum (+) or without serum (-) or pretreated with the inhibitors rapamycin (250 nM) or DMSO (0.5%, control). (B) Western blotting of indicated proteins in HEK293 cells expressing myc or myc-Rheb and pretreated with rapamycin or DMSO as in (A). (C) Western blotting of indicated proteins in HEK293 cells expressing myc or myc-Rheb and pretreated with inhibitors of MAPK (PD98059, 50 mM) or PI3K (wortmannin, 100 nM), rapamycin, or DMSO.

    Cell Rep 2015 10.1016/j.celrep.2015.01.014. Rapamycin (Sirolimus) purchased from Selleck.

    Autophagy induced by PL-0N and PL may restrict LPS-induced inflammatory responses in RAW264.7 cells. LPS induced autophagy in RAW264.7 cells. Cells were incubated with 1 mM 3-MA or 10 uM Rapamycin in the absence or presence of LPS (1 ug/mL) for 16 h. Then immunofluorescence for LC3 was visualized using a Zeiss LSM 710 confocal microscope.

    Biochem Pharmacol 2015 95(3), 156-69. Rapamycin (Sirolimus) purchased from Selleck.

  • Inhibition of mTOR activity may be responsible for sorafenib-induced down-regulation of survivin. H1299 cells were treated with the indicated concentration of RAD001 or Rapamycin for 48 h. Then H1299 cells were incubated with or without 5 μM sorafenib, with or without 5 μM RAD001, and with or without 2 μM rapamycin for 48 h.  The indicated protein levels were determined by Western blot analysis. β-Actin protein levels were measured as loading controls.

     

     

    Biochem Pharmacol 2011 82, 216-226. Rapamycin (Sirolimus) purchased from Selleck.

    Rapamycin (RPM) inhibits OA-induced lipogenesis. Male SD rats were divided into three groups, and then treated as follows for seven days: group I (control; Ctrl), normal diet + vehicle; group II (OA), 1% OA diet + vehicle; group III (OA + RPM), 1% OA diet + RPM. (A) Hepatic TG concentrations were determined using the serum triglyceride determination kit. (B) Fixed liver sections were subjected to HE and Oil Red O staining as well as immunohistochemistry assays with SREBP-1 antibody. Representative microphotographs of liver specimens from all groups of rats are shown. (C) The levels of mRNA of the indicated genes involved in lipogenesis were determined by real-time PCR. Each bar represents the mean ±SE of the results obtained from six rats. * P < 0.05, ** P < 0.01, *** P < 0.001.

    J Lipid Res 2011 52, 1617-1625. Rapamycin (Sirolimus) purchased from Selleck.

  • Immunophilins participate in SOCE activation by CN-dependent but also CN-independent signaling pathways. Fura-2 loaded platelets were suspended in HBS and subsequently incubated at 37oC for 30 min with rapamycin (500 nM). Once incubation time was over, platelets were stimulated with TG (200 nM) in a calcium free-HBS (EGTA 100 μM was added as indicated the by arrowhead) and 4 min later CaCl2 (300 µM) was added to visualized calcium entry. Changes in fura-2 fluorescence were monitored using the 340/380nm ratio and calibrated in terms of [Ca2+]c . Traces are representative of four to six independent experiments. *,**, *** represents p < 0.05, p < 0.01 and p <0.001, respect control platelets.

    Biochim Biophys Acta 2013 1833(3), 652-62. Rapamycin (Sirolimus) purchased from Selleck.

    Tuberc Respir Dis 2013 75(1), 9-17. Rapamycin (Sirolimus) purchased from Selleck.

  • 2013 Dr. Zhang of Tianjin Medical University. Rapamycin (Sirolimus) purchased from Selleck.

    Rapamycin inhibits growth-dependent TCTP induction. Cells were serum-starved for 24h and restimulated with 20% FBS for the indicated times in the presence or absence of rapamycin. The graph shows the relative TCTP signal, corrected for the loading control.

    2011 Dr.Ulrich Bommer of University of Wollongong. Rapamycin (Sirolimus) purchased from Selleck.

Purity & Quality Control

Choose Selective mTOR Inhibitors

Biological Activity

Description Rapamycin (Sirolimus) is a specific mTOR inhibitor with IC50 of ~0.1 nM HEK293 cells.
Targets
mTOR [1]
(HEK293 cells)
~0.1 nM
In vitro

Rapamycin inhibits endogenous mTOR activity in HEK293 cells with IC50 of ~0.1 nM, more potently than iRap and AP21967 with IC50 of ~5 nM and ~10 nM, respectively. [1] In Saccharomyces cerevisiae, Rapamycin treatment induces a severe G1/S cell cycle arrest and inhibition of translation initiation to levels below 20% of control. [2] Rapamycin significantly inhibits the cell viability of T98G and U87-MG in a dose-dependent manner with IC50 of 2 nM and 1 μM, respectively, while displaying little activity against U373-MG cells with IC50 of >25 μM despite the similar extent of the inhibition of mTOR signaling. Rapamycin (100 nM) induces G1 arrest and autophagy but not apoptosis in Rapamycin-sensitive U87-MG and T98G cells by inhibiting the function of mTOR. [3]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
HT-29 MXnDfZRwfG:6aXOgRZN{[Xl? M2\qUVExKG6P NIizeXM4OiCq NILsV2dFVVOR M3rEW3BwfGWwdHnheIV{KGOjbYD0c5Rp\WOrbj3pcoR2[2WmIHP5eI91d3irY3n0fS=> M2rrdlI1QTByOEez
HT-29 M2XhWGN6fG:2b4jpZ{BCe3OjeR?= MkXnNVAhdk1? NHjwfGo4OiCq NInvOXFFVVOR NVP5emc{WG:2ZX70bYF1\XNiZHnnbZRwgGmwLXnu[JVk\WRiY4n0c5RwgGmlaYT5 NFPTSYgzPDlyMEi3Ny=>
HT-29 M4m4[2N6fG:2b4jpZ{BCe3OjeR?= M1TXcVExKG6P NHHtToQ4OiCq NFq1RVVFVVOR NX7oRWZRWG:2ZX70bYF1\XNiNT3mcJVwem:3cnHjbYwucW6mdXPl[EBkgXSxdH;4bYNqfHl? MXuyOFkxODh5Mx?=
PC3 M4TodWtqdmG|ZTDBd5NigQ>? NVHSfWMyOTByIH7N MXKxJIg> M{LUUWROW09? NHfnTlBRd3SnboTsfUBqdmirYnn0d{BuXE:ULX3l[IlifGWmIGO2JJBpd3OyaH;yfYxifGmxbjD3bZRpKEmFNUCgc4YhRDFyIH7NMi=> NVr1SW9LOjF7N{i2PFM>
PC3 NITncWlMcW6jc3WgRZN{[Xl? MXixNFAhdk1? M{PRUlEhcA>? M4ryeWROW09? M13VbGRw\XNibn;0JIlvcGmkaYSgcXRQWi2vZXTpZZRm\CCDa4SgdIhwe3Cqb4L5cIF1cW:w MXqyNVk4QDZ6Mx?=
PC3 NWXSO2pKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYOxMlUh|ryP M3:wTFEhcA>? NV7qVY54TE2VTx?= NUHzVlRQUW6mdXPld{BidnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIGDDN{Bk\WyuczD3bZRpKEmFNUCgc4YhRDFyIH7N NEPnSXMzOTl5OE[4Ny=>
HEK293 MYrGeY5kfGmxbjDBd5NigQ>? M3ToUVExOCCwTR?= MWC4JIg> MmTXSG1UVw>? MmLyTY5pcWKrdIOgWHBCNWmwZIXj[YQh\GWpcnHkZZRqd25ib3[gVIRk\DRid3n0bEBGSzVyIH;mJFUxKG6P MmHUNlE2Ozl|MEG=
BT-20 NInqeY9McW6jc3WgRZN{[Xl? M4HkcFIxKM7:TR?= NX\CRmZuTE2VTx?= M124e2Rw\XNibn;0JIlvcGmkaYSgcXRQWkN{IHTldIVv\GWwdDDwRYtVKFN2N{OgdIhwe3Cqb4L5cIF1cW:w NILtb5kzOTN3M{W1NS=>
U937 NXfMTIIySW62aXLhZ5RmemmjbDDBd5NigQ>? NYLNcYJ3PTBizszN NWLGWVM5PDhiaB?= MnzRSG1UVw>? NF3EVVRKdmS3Y3XzJIFvfGmkYXP0[ZJq[WxiYXP0bZZqfHliYXfhbY5{fCC5aXzkJJR6eGViTHXnbY9v\WyuYTDwcoV2dW:yaHnsZUBRcGmuYXTlcJBpcWFvMTDKVlMzKGmwIGW5N|ch[2WubIO= NXH1dWo2OjFzNEKxNFY>
U937 NYDGTZNFSW62aXLhZ5RmemmjbDDBd5NigQ>? MXy1NEDPxE1? MUC0PEBp MlPOSG1UVw>? M{PJ[WRw\XNibn;0JIlv\HWlZTDhcpRq[mGldHXybYFtKGGldHn2bZR6KGGpYXnud5QhVUmSIIDyc5RmcW5vZHXmbYNq\W62IFzl[4lwdmWubHGgdI5mfW2xcHjpcIEhUlJ|Mj2yJIlvKFV7M{egZ4VtdHN? NIjCcHEzOTF2MkGwOi=>
U937 MVfBcpRq[mGldHXybYFtKEG|c3H5 Mn7SOVAh|ryP NIfRcGY1QCCq MUfEUXNQ NXHmTIJRTG:nczDuc5QhcW6mdXPlJIFvfGmkYXP0[ZJq[WxiYXP0bZZqfHliYXfhbY5{fCCHc3Po[ZJq[2irYTDjc4xqKEiEMUCxJIlvKFV7M{egZ4VtdHN? NInrepEzOTF2MkGwOi=>
MCF-7 NEP3TGhCfXSxcHjh[5khSXO|YYm= MVSzNEBvVQ>? MYG0JIg> MXHEUXNQ NXjnNIVHUW6mdXPld{BifXSxcHjh[5k> MXKyNFAzQDF|NB?=
U87MG MkLVT4lv[XOnIFHzd4F6 M{e0clEh|ryP NWL1WmJlPiCq Mn\iSG1UVw>? M{LmZ3BwfGWwdHz5JIlvcGmkaYTzJI1VV1JvbXXkbYF1\WRiU{[gdIhwe3Cqb4L5cIF1cW:w MUmxPVg1QDRyNB?=
U87MG MXjLbY5ie2ViQYPzZZk> NYLKZ5dxOSEQvF2= NFLBfHI3KGh? M4rZeWROW09? MYXQc5RmdnSueTDpcohq[mm2czC0SWJROSiWN{CpJJBpd3OyaH;yfYxifGmxbh?= NV7SfZdGOTl6NEi0NFQ>
U87MG M{LTdWtqdmG|ZTDBd5NigQ>? NFziXokyKM7:TR?= MVO2JIg> MU\EUXNQ Mn7YSI9meyCwb4SgbY5pcWKrdDDtWG9TNW2nZHnheIVlKEGtdDDwbI9{eGixconsZZRqd25? NWrWRVd6OTl6NEi0NFQ>
U87MG NXn0UotMU2mwYYPlJGF{e2G7 M2n0OlEh|ryP MYG2JIg> MUnEUXNQ MlmySI9meyCwb4SgbY5pcWKrdDDQMVRGSlBzKGSzO{81PilicHjvd5Bpd3K7bHH0bY9v M4\yOFE6QDR6NEC0
COS7 cells expressing EGFP-HDQ74/rheb MYPBeZRweGijZ4mgRZN{[Xl? M1XyXlAvOiEQvF2= M2XjVFI1KGh? MX3EUXNQ NEHnbG9KdmS3Y3XzJIF2fG:yaHHnfS=> NHqwbIUyQDN7MUm0PS=>
COS7 cells expressing EGFP-LC3 NGO0ZXlCfXSxcHjh[5khSXO|YYm= NGHsNm4xNjJizszN NUnEZnpuOjRiaB?= M3HrfGROW09? MXfJcoR2[2W|IHH1eI9xcGGpeR?= MXGxPFM6OTl2OR?=
H4 NIDGfppHfW6ldHnvckBCe3OjeR?= Mlz5NE4zKM7:TR?= MWKyOEBp M1TabmROW09? MoXXTY5kemWjc3XzJJRp\SC{YYTpc{Bw\iCuaXfoeEBkcGGrbjCzJJN2[nWwaYSgNkB1dyCuaXfoeEBkcGGrbjCzJJN2[nWwaYSgNUBqdiCqdX3hckBJPCClZXzsdy=> MmrzNVgxOjR3OES=
HeLa NXv0TnlxTnWwY4Tpc44hSXO|YYm= MlTONVAxKG6P NFvs[FI{PiCq NHTPc2lFVVOR MXvJcoR2[2W|IF\SRkBMOjB7NWCsJHQzODl6TDygW|IyODGIIH31eIFvfC23YnnxeYl1cW6FIHnueIVz[WO2aX;u NIHIe2wyPzV4M{O4OS=>
HeLa NVz1W4FkTnWwY4Tpc44hSXO|YYm= MYixNFAhdk1? NIm0OWw{PiCq MnS4SG1UVw>? MWXJcoR2[2W|IF\SRkBYOjFyMV[gcZV1[W62LYXibZF2cXSrblOgbY51\XKjY4Tpc44> M3\4fVE4PTZ|M{i1
HeLa NEe3fYZHfW6ldHnvckBCe3OjeR?= NHfJdosyODBibl2= MX[zOkBp MlnxSG1UVw>? NFOx[45KdmS3Y3XzJGZTSi2IS1LQJINwdXCuZYigbY51\XKjY4Tpc44> M1j1cVE4PTZ|M{i1
SYF NI\mZmNHfW6ldHnvckBCe3OjeR?= M{XZR|ExOCCwTR?= NH;OVGUzPCCq NFqzfpZFVVOR NX;1fo9JUW6mdXPld{BHWkJvRlvCVEBkd22ybHX4JIlvfGW{YXP0bY9v MkTqNVc2PjN|OEW=
SYF MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYXidppKOTByIH7N NWHHfHpTOjRiaB?= NHnHd|VFVVOR Mo\WTY5lfWOnczDhcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IGPZSkBk\Wyucx?= MlzaNVc2PjN|OEW=
HEK293T Mn[5RY51cX[rcnHsJGF{e2G7 Mmq2NUBvVQ>? NFPweJQ1KGR? MX3EUXNQ NVn4[WhSUW6mdXPld{BidnSrdnnyZYwh[WO2aY\peJkh[WejaX7zeEBJUVZzIGK1JJdqfGhiRVO1NEBw\iByLkGgcm0> NV7jWHVGOTd2OEW1NFE>
HEK293T MmHlRY51cX[rcnHsJGF{e2G7 MVKxJI5O MVS0JIQ> NYLlT|ZGTE2VTx?= NX;rcXFnUW6mdXPld{BidnSrdnnyZYwh[WO2aY\peJkh[WejaX7zeEBJUVZzIGi0JJdqfGhiRVO1NEBw\iByLkOgcm0> M3TxdVE4PDh3NUCx
PBMC MXXGeY5kfGmxbjDBd5NigQ>? MnvaNUBvVQ>? NXjFbmZ3OTRiZB?= M3G3[GROW09? NEnkfGJT\WS3Y3XzJGNEWjViZHXud4l1gQ>? NVz2PHg4OTd2OEW1NFE>
PBMC MlS5SpVv[3Srb36gRZN{[Xl? NEXuNoQyKG6P NYPafIdyOTRiZB?= NEDHd3ZFVVOR Mln4SI9meyCwb4SgZYZn\WO2IFPYR3I1KGSnboPpeJk> M4\2RlE4PDh3NUCx
HEK293 cells NHmxRnVMcW6jc3WgRZN{[Xl? NUj4ToFWPTBibl2= MV[0OUBucW5? NYLifmIzTE2VTx?= M1iyRWlvcGmkaYTzJI1VV1Jia3nuZZNmKGGldHn2bZR6KHerdHigTWM2OCCxZjCwMlEhdk1? NWe0b|RQOTd|NUC5OVM>
Drosophila melanogaster S2 cells transfected with N-luc and C-luc M2[yeWZ2dmO2aX;uJGF{e2G7 NY\TZ|NLOTByIH7N MU[0JIg> Mn\YSG1UVw>? MnLjTY5lfWOnczDseYNq\mW{YYPlJJBzd3SnaX6geJJidnNvc4DsbYNqdmdiaX6gSJJwe2:yaHnsZUBu\Wyjbn;nZZN1\XJiU{KgZ4VtdHNidILhcpNn\WO2ZXSge4l1cCCQLXz1Z{BidmRiQz3seYM> M1P4RlE4OTJ6Mk[y
Human mixed lymphocyte M1XMVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4n6c|Uhdk1? MX;EUXNQ NHvhWYdKSzVyPUGuOkBvVS5? NHnmWFUyPjF6NUi2OS=>
Lewis rat lymph node cells M2T5S2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWq1JO69VQ>? MnO0SG1UVw>? MXnJR|UxRTJwNjFOwG0> MVexOlE5PTh4NR?=
cells from the thymus of normal BALB/c mice MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlO0NVAhdk1? MlPsO|IhcA>? M1fldGROW09? NF\BSJlKdmirYnn0d{BtgW2yaH;wdo9tcW[ncnH0bY9vKCiOQV[pJJdqfGhiSVO1NEBw\iB|IH7N M{DNV|ExODJzOUS4
MRK-nu-1 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV;UNoF5UUN3ME2wMlg1PSCyTR?= NXLRXXluW0GQR1XS
OCUB-M MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2n6VmlEPTB;NT6yOEBxVQ>? NIjUelJUSU6JRWK=
SF539 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYPJR|UxRTFzLk[gdG0> NVjROYU2W0GQR1XS
ES4 MknsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXTJR|UxRTJzLkWgdG0> M1XCZXNCVkeHUh?=
RL95-2 M3uzfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M17FdmlEPTB;MUC3JJBO NV:yWlVYW0GQR1XS
LC-2-ad M3r0cGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVvJR|UxRTR{MzDwUS=> NFvFT2pUSU6JRWK=
Daudi NV;5OIc2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHj4O3hKSzVyPUSzOEBxVQ>? M1zlZXNCVkeHUh?=
NTERA-S-cl-D1 M2rvUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXPJR|UxRTR2MzDwUS=> M{myZnNCVkeHUh?=
OS-RC-2 NVLxPJdKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnrMTWM2OD14NUKgdG0> NHHHUZNUSU6JRWK=
VA-ES-BJ M4njW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYnJR|UxRTd{MzDwUS=> M2O4NHNCVkeHUh?=
GR-ST NXHwT|FWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIPJcIhKSzVyPUi0OkBxVQ>? NVHkVJRpW0GQR1XS
SW872 M{DRemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX36U4VqUUN3ME24OFYheE1? MWDTRW5ITVJ?
NOS-1 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH7QVotKSzVyPUi3NUBxVQ>? M4rlV3NCVkeHUh?=
MC116 NG\4d21Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NG\NRVBKSzVyPUm4OUBxVQ>? MXHTRW5ITVJ?
NCI-H1355 MoP1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoS3TWM2OD1zLkCxJI5O NITJPGdUSU6JRWK=
RPMI-8226 MlLlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYLJR|UxRTFwMUmgcm0> MnvkV2FPT0WU
TE-15 NGX0fXJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGHLbppKSzVyPUGuN|Yhdk1? MnvHV2FPT0WU
Ramos-2G6-4C10 NUTBWXhYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXTJR|UxRTFwNE[gcm0> Mni2V2FPT0WU
KU812 NIPsfohIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NED5NYVKSzVyPUKuNFEhdk1? Ml2wV2FPT0WU
EW-1 NYmwbnR3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVzJR|UxRTJwMUegcm0> NFzmeotUSU6JRWK=
KS-1 NHSxOJZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUfJR|UxRTJwNEWgcm0> MnvRV2FPT0WU
SK-LMS-1 MlPCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2WwWmlEPTB;Mj60PUBvVQ>? MmHVV2FPT0WU
TGBC1TKB NXq5elJtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVfHSGVwUUN3ME2yMlY6KG6P MUDTRW5ITVJ?
TE-6 MlfqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4q2cWlEPTB;Mj63O{BvVQ>? NVTIdlZbW0GQR1XS
ETK-1 M3nlUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlvRTWM2OD1{LkiyJI5O M2GzW3NCVkeHUh?=
BE-13 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXPJR|UxRTJwOUmgcm0> NIDDd2lUSU6JRWK=
A3-KAW M2\xWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYHJR|UxRTJwOUmgcm0> NYPZRnlMW0GQR1XS
TE-10 Mn7US5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mmq5TWM2OD1|LkOgcm0> NV;UXWRTW0GQR1XS
DOHH-2 M4XDOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVTxXI5KUUN3ME2zMlM2KG6P Mn60V2FPT0WU
ES6 NULWUpExT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlvPTWM2OD1|LkSzJI5O NUCwO|JTW0GQR1XS
OPM-2 M2TFRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYjJR|UxRTRwMUWgcm0> M4n0T3NCVkeHUh?=
SH-4 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXGyS2NuUUN3ME20MlM1KG6P M3myWnNCVkeHUh?=
NB13 M{jQfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFf3XGxKSzVyPUSuN|Yhdk1? MYfTRW5ITVJ?
HUTU-80 NGTpdHdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYrJR|UxRTRwNEKgcm0> NHjWPWZUSU6JRWK=
CCRF-CEM NVviR2tOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkjYTWM2OD12Lkm0JI5O MmXQV2FPT0WU
TGBC24TKB M1fpdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYfJR|UxRTVwNUGgcm0> MWHTRW5ITVJ?
697 NV62V3U1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUTENok{UUN3ME22MlI5KG6P MnfBV2FPT0WU
J-RT3-T3-5 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MULJR|UxRTZwNE[gcm0> MYjTRW5ITVJ?
KALS-1 MnKyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3vZW2lEPTB;Nj61OkBvVQ>? MlXGV2FPT0WU
no-10 MljCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4[2[2lEPTB;Nz6yPUBvVQ>? NY\1bJRHW0GQR1XS
SK-NEP-1 NV7LOlQ6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEXVdWpKSzVyPUiuO|khdk1? MlfHV2FPT0WU
L-540 NYXLO3FRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVTJR|UxRTFyLkSyJI5O Ml21V2FPT0WU
JiyoyeP-2003 NIDyR4JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1rtTGlEPTB;MUCuPVQhdk1? MUXTRW5ITVJ?
HH M1;EbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV\JR|UxRTFzLkO5JI5O MmPlV2FPT0WU
SR MnyzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHL4NY1KSzVyPUGxMlQ2KG6P MmezV2FPT0WU
QIMR-WIL NUfkN2FST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWnOWoJtUUN3ME2xNU45PSCwTR?= MV7TRW5ITVJ?
A4-Fuk NHPkXHBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX;JR|UxRTF|LkGyJI5O NWnDZ5VyW0GQR1XS
CESS NFPsdoxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1HEXWlEPTB;MUOuNVMhdk1? NF7OTGpUSU6JRWK=
KE-37 NVHtNZVxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXW3NYxKUUN3ME2xOk4xPyCwTR?= NUHXb2l2W0GQR1XS
SK-UT-1 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1HhcmlEPTB;MU[uPFEhdk1? MmrFV2FPT0WU
SIG-M5 NFvxT2NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M13WU2lEPTB;MUeuNlUhdk1? MYnTRW5ITVJ?
HT NXLkXo46T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYPtOJJPUUN3ME2xO{43KG6P NYTt[ppZW0GQR1XS
DEL M4i0fWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{f2Z2lEPTB;MUeuPVkhdk1? MoXJV2FPT0WU
SK-PN-DW NX3Kb25RT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEHCSGtKSzVyPUKwMlI{KG6P M2r1eHNCVkeHUh?=
RPMI-8402 NWXSTpBOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYPpS5FKUUN3ME2yNU44PyCwTR?= NIi3cIpUSU6JRWK=
RPMI-6666 NVrB[3VwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmjlTWM2OD1{ND60NkBvVQ>? NEC1XJlUSU6JRWK=
NCI-H720 Mnq3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{HGbmlEPTB;MkWuOFEhdk1? NELtSoNUSU6JRWK=
EW-16 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUTW[Y9UUUN3ME2yOk45PyCwTR?= M1rtW3NCVkeHUh?=
BL-70 M4[3ZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGmyZoJKSzVyPUK4MlM5KG6P Mn;6V2FPT0WU
SF126 MlvmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmrKTWM2OD1|MD6zPEBvVQ>? NWL6T5JYW0GQR1XS
BC-1 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXPBO3hTUUN3ME2zNU4zPiCwTR?= NYnxWZp[W0GQR1XS
MHH-PREB-1 NG\M[|RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUX6SlRZUUN3ME2zNk41PCCwTR?= NWXwbmxmW0GQR1XS
A101D MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{TyZWlEPTB;M{KuOlIhdk1? MojrV2FPT0WU
NMC-G1 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVztPHc6UUN3ME2zN{43PyCwTR?= MX7TRW5ITVJ?
LB1047-RCC NGjlR2dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUe0Wm9QUUN3ME2zOE43QSCwTR?= NWHlOJgxW0GQR1XS
EM-2 NHrLb|JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVX4cllkUUN3ME2zPE42OyCwTR?= MX3TRW5ITVJ?
COLO-684 NG\OV2lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1Pn[WlEPTB;M{muPEBvVQ>? MUPTRW5ITVJ?
Becker MnvOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnToTWM2OD12MT6wOUBvVQ>? NUHsVIR4W0GQR1XS
BL-41 M2W2SWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYTJR|UxRTR|Lk[2JI5O MUPTRW5ITVJ?
MDA-MB-134-VI MlPwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml\VTWM2OD12ND6wNkBvVQ>? MnfQV2FPT0WU
L-363 NVLueVZET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFHSN4xKSzVyPUS0Mlc{KG6P MXfTRW5ITVJ?
ECC4 NGrRempIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVLrdplsUUN3ME20OE44QCCwTR?= NFzXSYJUSU6JRWK=
A388 NUfyd|ZoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX3JR|UxRTR2LkiyJI5O NHnkfHZUSU6JRWK=
HEL M2HWO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkTKTWM2OD12OT63PUBvVQ>? NIXTRnZUSU6JRWK=
RKO NUPQdGpbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1z4TWlEPTB;NUCuNlkhdk1? MmHuV2FPT0WU
KINGS-1 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF;IcWRKSzVyPUWxMlU2KG6P M{TQfXNCVkeHUh?=
EB-3 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYTJR|UxRTV{Lk[3JI5O MXrTRW5ITVJ?
ARH-77 M3juNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1vWXGlEPTB;NUKuPEBvVQ>? M2\adnNCVkeHUh?=
GCIY NXzYN3RrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYjFfZcxUUN3ME21N{41PiCwTR?= NGD3NI1USU6JRWK=
NCI-H1304 NHmxWmNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWmxV4RPUUN3ME21O{4zOiCwTR?= MVjTRW5ITVJ?
KARPAS-299 M3;2PWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Moq0TWM2OD14MT64NkBvVQ>? NVq1N2I3W0GQR1XS
IA-LM M3jiTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn7yTWM2OD14OD6xN{BvVQ>? M1TiNnNCVkeHUh?=
GI-1 NXrWOWlUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlPITWM2OD15MD6zPUBvVQ>? MXzTRW5ITVJ?
TE-11 M2LRbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2fxXGlEPTB;N{euNVchdk1? MWrTRW5ITVJ?
LS-411N Ml;zS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NULYVYd[UUN3ME23O{42PyCwTR?= NGixWm9USU6JRWK=
no-11 NUDiTVNXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlnXTWM2OD16Mz6yOEBvVQ>? M2\qRXNCVkeHUh?=
MV-4-11 NFXXOFJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFj1TmFKSzVyPUizMlc{KG6P NEfNUmlUSU6JRWK=
BV-173 NX6wcYt7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmrwTWM2OD16Mz65O{BvVQ>? M4rHZ3NCVkeHUh?=
CMK NVHVcmVoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXi3b4dPUUN3ME24OE4yPiCwTR?= MUDTRW5ITVJ?
LC4-1 M1n6dmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1HPNmlEPTB;OE[uO|Ihdk1? M2\2TXNCVkeHUh?=
COR-L279 NVu0bZNST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn7RTWM2OD16Nz6yOUBvVQ>? Mm\4V2FPT0WU
NCI-H209 NWDiRYw6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MorSTWM2OD16Nz60NUBvVQ>? NGr1eWdUSU6JRWK=
Raji M4\qc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYXJR|UxRTh7LkeyJI5O M3e5WHNCVkeHUh?=
LB996-RCC Ml3PS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mne5TWM2OD17Mz60N{BvVQ>? NF3hNJpUSU6JRWK=
NCI-H526 NYmyUplYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{PEO2lEPTB;OUOuOVkhdk1? MUXTRW5ITVJ?
KGN MnfjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGOxVplKSzVyPUm2MlI6KG6P MUnTRW5ITVJ?
MOLT-4 MofjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWHIc|JvUUN3ME25Ok44QSCwTR?= M4jzenNCVkeHUh?=
PF-382 NInr[JZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn6wTWM2OD17Nj63PUBvVQ>? M{jxXHNCVkeHUh?=
BC-3 M3fRd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{mzR2lEPTB;OUmuNVghdk1? NWHVNlQ2W0GQR1XS
KARPAS-422 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXLJR|UxRTFyMj6wPUBvVQ>? M37QSnNCVkeHUh?=
SBC-1 NV3lR4t1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml3pTWM2OD1zMEeuO|Uhdk1? MmDpV2FPT0WU
LC-1F M3zXUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlrWTWM2OD1zMEiuNFUhdk1? NWTkW5l7W0GQR1XS
GB-1 MoXPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkDvTWM2OD1zMEmuNFIhdk1? MVLTRW5ITVJ?
SNB75 NH\pWFVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2jSOmlEPTB;MUG5MlY6KG6P NYjJWXpmW0GQR1XS
BB65-RCC MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlfUTWM2OD1zMUmuPVMhdk1? NV\zSZRoW0GQR1XS
NCI-N87 MlfwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVPJR|UxRTF{MT65PEBvVQ>? MV7TRW5ITVJ?
IST-MEL1 MofmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEH2b21KSzVyPUGyNk4{QCCwTR?= M3fVZnNCVkeHUh?=
HOP-62 NWjkOZpNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3X3TWlEPTB;MUK2Mlg6KG6P MYXTRW5ITVJ?
ACN NHfNRmFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWLJR|UxRTF2Nj63OUBvVQ>? NGPlcGxUSU6JRWK=
DMS-114 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXXJR|UxRTF3MD62O{BvVQ>? NELFS4xUSU6JRWK=
MLMA Mk[2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4[5NGlEPTB;MUW5Mlg5KG6P MmX5V2FPT0WU
HT-144 NEDNd|NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2\4TWlEPTB;MU[1MlQ{KG6P NUPUdXE2W0GQR1XS
C2BBe1 NFHIdI5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4PFOWlEPTB;MU[3Mlc3KG6P MUjTRW5ITVJ?
L-428 NF3yUnJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIDxW3NKSzVyPUG3O{44KG6P MnnVV2FPT0WU
DU-4475 NILx[GJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUjJR|UxRTF6Nz62PEBvVQ>? M{KxSXNCVkeHUh?=
CP67-MEL MnLPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkLETWM2OD1zOUmuN|ghdk1? MnvnV2FPT0WU
MEG-01 NWHKd5ZNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1vkXmlEPTB;MkCxMlk3KG6P NWTjdpBlW0GQR1XS
IST-SL2 NGjKbFRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWDESXY{UUN3ME2yNFgvPjNibl2= NEGzV3RUSU6JRWK=
ES8 MoLZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MY\JR|UxRTJ{NT65OEBvVQ>? NU\oPYFPW0GQR1XS
COLO-800 MonoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVjhcXp1UUN3ME2yN|UvOjhibl2= NIe4S3hUSU6JRWK=
MFH-ino M{PXWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M33QNmlEPTB;MkO1Mlg1KG6P NF6wVFlUSU6JRWK=
OVCAR-4 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkTFTWM2OD1{M{euNlQhdk1? MVHTRW5ITVJ?
PSN1 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MljiTWM2OD1{NEKuO|Ehdk1? MXXTRW5ITVJ?
EW-12 M{m5[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXmwN5U6UUN3ME2yOFMvOSCwTR?= MXLTRW5ITVJ?
HCC1599 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGrUcoxKSzVyPUK2NU41PyCwTR?= MoLtV2FPT0WU
SJSA-1 M1vScmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NE\teo1KSzVyPUK3NU41PiCwTR?= Mmr2V2FPT0WU
ST486 NWTJN3NnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYfJR|UxRTJ7Nj6xOEBvVQ>? NGq4d45USU6JRWK=
NOMO-1 M{T3XWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEnDWWJKSzVyPUOwNE4zOSCwTR?= M4rQUnNCVkeHUh?=
MN-60 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVTJR|UxRTNyNT6zNkBvVQ>? NXK5NpRlW0GQR1XS
HCC1187 M1\ueWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3OyVWlEPTB;M{C3MlI2KG6P M{j2cHNCVkeHUh?=
SW982 NUnBOphlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVzJR|UxRTNzND63OUBvVQ>? MkH0V2FPT0WU
LB647-SCLC MlH4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVrJR|UxRTN{OD63NUBvVQ>? MWrTRW5ITVJ?
HC-1 NXThfod2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXrJR|UxRTN|NT61JI5O NFq1W4hUSU6JRWK=
EHEB MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIP6[m1KSzVyPUOzO{42OiCwTR?= M1PH[nNCVkeHUh?=
TUR MlHHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4n5NWlEPTB;M{[zMlk2KG6P MmTHV2FPT0WU
LU-139 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXPJR|UxRTN5OD6wNkBvVQ>? NHPjXoVUSU6JRWK=
NB1 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MluxTWM2OD1|OESuOFUhdk1? Ml;VV2FPT0WU
BB30-HNC NGrYS49Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NI[3eHhKSzVyPUO4PE4{OiCwTR?= NUH1TIZZW0GQR1XS
HAL-01 NIj2RoJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF7nendKSzVyPUO4PU4zPiCwTR?= MV3TRW5ITVJ?
K5 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MonzTWM2OD12MUGuN|chdk1? NGDSV3JUSU6JRWK=
MZ2-MEL MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXL1WFQ4UUN3ME20NVMvPjRibl2= NFHPN5BUSU6JRWK=
RXF393 NYe2eYE6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlOxTWM2OD12MU[uOFUhdk1? NGW3S5dUSU6JRWK=
NCI-H1648 MnvkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXf0emZTUUN3ME20NVcvPTNibl2= MYfTRW5ITVJ?
TE-12 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX\JR|UxRTR|ND6yOkBvVQ>? NIW3ZmdUSU6JRWK=
EoL-1- MoLIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4fnN2lEPTB;NEO3Mlk5KG6P MlfzV2FPT0WU
JAR MojrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXzJR|UxRTR|OD62NkBvVQ>? NXvRZmZkW0GQR1XS
DSH1 M{DWRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHrDdm5KSzVyPUS1PE46OSCwTR?= NVS0RVNsW0GQR1XS
NCI-H187 MkfHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUPJR|UxRTR4Mj64NUBvVQ>? M2PqWnNCVkeHUh?=
HCE-4 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWXOcWpIUUN3ME20O|cvPjZibl2= NUG2eZh7W0GQR1XS
8-MG-BA NVn4VFk5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmfJTWM2OD13OEGuOVIhdk1? MnjoV2FPT0WU
KLE NYXQUoZrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYP4Z|B1UUN3ME21PFUvOiCwTR?= MmPNV2FPT0WU
KNS-42 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnvsTWM2OD13OE[uPFEhdk1? NVfsOFJZW0GQR1XS
MSTO-211H MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXzGVlFPUUN3ME22NFkvPzRibl2= NFfUboRUSU6JRWK=
GDM-1 NWDaU2FoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{XwOmlEPTB;NkG0MlA6KG6P NV6zOlkzW0GQR1XS
TE-1 MoWwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NETtT|dKSzVyPU[0Ok4yOiCwTR?= MVXTRW5ITVJ?
BT-474 NGLMRVFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYTP[W9lUUN3ME22OFcvODZibl2= MYjTRW5ITVJ?
KARPAS-45 Mlr3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmT6TWM2OD14NEeuOkBvVQ>? MnftV2FPT0WU
MOLT-16 NWryVYFlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVvJR|UxRTZ2Nz65N{BvVQ>? MnrJV2FPT0WU
KURAMOCHI MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWHNc2pEUUN3ME22OVcvPTFibl2= MnzLV2FPT0WU
K-562 MlnVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NY\EVHY1UUN3ME22OlkvPTFibl2= MknXV2FPT0WU
EKVX NHfhZVVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mnj2TWM2OD14N{KuO|Ehdk1? MUXTRW5ITVJ?
GAK M2C2dGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUXJR|UxRTZ5NT6zJI5O M4XvenNCVkeHUh?=
NCI-SNU-5 M3fYfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV\JR|UxRTZ7MD6wNUBvVQ>? NFfSbJZUSU6JRWK=
NCI-H2126 NVrSVodoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmHGTWM2OD15Mk[uPFchdk1? NGjjZ4hUSU6JRWK=
CTV-1 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYKx[lZPUUN3ME23OFQvQSCwTR?= NGXCW3pUSU6JRWK=
SW962 MoS5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWK5R2ozUUN3ME23OFgvPDRibl2= NXjSTmgyW0GQR1XS
MONO-MAC-6 NIfJT25Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{PtW2lEPTB;N{W2Mlk{KG6P MoLPV2FPT0WU
NCI-H748 NXzoPIhzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEHJV2xKSzVyPUe1PE46QSCwTR?= NHz5UJpUSU6JRWK=
NCI-H524 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MY\JR|UxRTd6MD63N{BvVQ>? M1rGd3NCVkeHUh?=
LS-123 NGjlV25Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEPm[lRKSzVyPUe5OU43QSCwTR?= NU\jVYJoW0GQR1XS
NB7 M3jDRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIDab4hKSzVyPUixOE4yPCCwTR?= MljhV2FPT0WU
LS-1034 M4jFN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXfSfYd[UUN3ME24NlgvQThibl2= MX7TRW5ITVJ?
TE-5 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoruTWM2OD16OEOuOVYhdk1? NGTOU|NUSU6JRWK=
A704 NILObVlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MofMTWM2OD16OUmuNVUhdk1? MkP2V2FPT0WU
TK10 Mn3wS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEj5XWpKSzVyPUmxOk4xOyCwTR?= NVqzPGlXW0GQR1XS
NCI-H345 M17yb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEnCcZpKSzVyPUm0N{4zOiCwTR?= MmnwV2FPT0WU
CGTH-W-1 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYHUN4UxUUN3ME25OFgvOTNibl2= MYXTRW5ITVJ?
NCI-H510A NUjlTWhCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXKzXXFsUUN3ME25PFUvOTJibl2= NFexbWtUSU6JRWK=
NCI-H1963 M17YT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWfJR|UxRTFwMEOyPVIh|ryP NWr2No5WW0GQR1XS
SCC-3 Mn23S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoS4TWM2OD1zLkCzOFE1KM7:TR?= NGC2OJBUSU6JRWK=
EW-11 NXvKOmo1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4G2NWlEPTB;MT6wPFc1OyEQvF2= NU\XS2VyW0GQR1XS
CPC-N MkDmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXLJR|UxRTFwMEi4JO69VQ>? NUfIbZlEW0GQR1XS
NCI-H1417 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXPWflV1UUN3ME2xMlEzOjZizszN NHXhXpFUSU6JRWK=
DG-75 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIfxfWtKSzVyPUGuNVYzQDVizszN NW[0fFd1W0GQR1XS
HD-MY-Z Mn;BS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{j2WGlEPTB;MT6xOlQyPiEQvF2= NXn6OVAzW0GQR1XS
ATN-1 M4rxNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MljKTWM2OD1zLkK2NlA6KM7:TR?= M{X2d3NCVkeHUh?=
KM-H2 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVLJR|UxRTFwMk[0NFgh|ryP NFHSNllUSU6JRWK=
NCI-H2081 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVrJR|UxRTFwMk[2N|ch|ryP MnmzV2FPT0WU
HL-60 NU\BNWxnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn3NTWM2OD1zLkK2PVU6KM7:TR?= MYfTRW5ITVJ?
DB M4\lS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkewTWM2OD1zLkK3NlQzKM7:TR?= M4\INnNCVkeHUh?=
NCI-H1522 M3n1VGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXzJR|UxRTFwMki4PFch|ryP MojYV2FPT0WU
AM-38 M4fvWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYDJR|UxRTFwM{C3NkDPxE1? MkH1V2FPT0WU
NCI-H446 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWC3TmFEUUN3ME2xMlMzOTJzIN88US=> M2rUZnNCVkeHUh?=
SU-DHL-1 NW\KOW83T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkPOTWM2OD1zLkOyPFAyKM7:TR?= NHrpO3pUSU6JRWK=
NH-12 MmfNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3jj[WlEPTB;MT6zOlM4PCEQvF2= MnTzV2FPT0WU
DMS-79 NH\RUIhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4HzfWlEPTB;MT6zOlg3PiEQvF2= MnfQV2FPT0WU
NCI-H716 NXLVZZlHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M12zR2lEPTB;MT6zPFk5PiEQvF2= MXLTRW5ITVJ?
ML-2 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYPjb4d6UUN3ME2xMlQyPTJ7IN88US=> MUTTRW5ITVJ?
NB10 M3vTNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF\WRYVKSzVyPUGuOFY3OzJizszN MmjYV2FPT0WU
ONS-76 M1myPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUjJR|UxRTFwNUO1Olkh|ryP M2rt[nNCVkeHUh?=
LOUCY MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUHJR|UxRTFwNUS2OVch|ryP NHrYTJNUSU6JRWK=
SCLC-21H NIPXPFZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUfJR|UxRTFwNUi1PFIh|ryP NGTzT2JUSU6JRWK=
TGW MlTLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXnTU|BNUUN3ME2xMlY{QTd3IN88US=> MXPTRW5ITVJ?
LXF-289 NVSwcWEzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVrwUYdqUUN3ME2xMlc{OjZ6IN88US=> M3TQU3NCVkeHUh?=
BB49-HNC NXnhTIhMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXzsNWNRUUN3ME2xMlc{PTh4IN88US=> MkW0V2FPT0WU
NCI-H747 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3\sU2lEPTB;MT63OVM1PiEQvF2= NHrISnFUSU6JRWK=
LU-165 NEPadplIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGTtPXJKSzVyPUGuPFQ6QDZizszN NUDxWox3W0GQR1XS
OMC-1 M2TEUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXrJR|UxRTFwOUWwOlYh|ryP M37UU3NCVkeHUh?=
RCC10RGB MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVXCeFAxUUN3ME2xMlk2QDF5IN88US=> MmjuV2FPT0WU
SW684 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkC1TWM2OD1zLkm2NFk6KM7:TR?= NXSwUYVqW0GQR1XS
TE-8 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnzaTWM2OD1{LkC1OVU6KM7:TR?= M{Wx[HNCVkeHUh?=
SK-N-DZ MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIDHXlVKSzVyPUKuNVMzPzRizszN MYLTRW5ITVJ?
EVSA-T NVHOO5kxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{HaTmlEPTB;Mj6xO|MyPSEQvF2= MXzTRW5ITVJ?
KASUMI-1 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVnaSVFTUUN3ME2yMlE5QDF3IN88US=> M4\QeXNCVkeHUh?=
NKM-1 NWjrfodPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWLJR|UxRTJwMkW0O|Ih|ryP M4mwWnNCVkeHUh?=
CAL-148 NX64TZVmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NETi[XFKSzVyPUKuN|M3OTRizszN MYPTRW5ITVJ?
NCI-H64 NXTIbppST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NU\ZUIc3UUN3ME2yMlM1OjN{IN88US=> NWrJb4czW0GQR1XS
KNS-81-FD Mn74S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2LiN2lEPTB;Mj6zOlYzKM7:TR?= MoXzV2FPT0WU
KM12 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGToWW1KSzVyPUKuOFA5OzlizszN NG\meI9USU6JRWK=
SW954 M{C0WWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHrCN|BKSzVyPUKuOFc4PzlizszN MkDCV2FPT0WU
NCI-H1395 MofNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX;UZ4JqUUN3ME2yMlUzPjR3IN88US=> M3\mWXNCVkeHUh?=
DJM-1 NIDKfGdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXTufW1yUUN3ME2yMlYxPjNizszN MoPaV2FPT0WU
COLO-668 M3XMTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1nSTWlEPTB;Mj64NlY6PSEQvF2= MXzTRW5ITVJ?
NCI-H1436 NV;Pc5N[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXHWPGl[UUN3ME2yMlg2PjF3IN88US=> NXjCTHdUW0GQR1XS
LB2241-RCC MlHqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYjJR|UxRTJwOE[4N|kh|ryP NUG0[WpOW0GQR1XS
GT3TKB MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3rXemlEPTB;Mj64PVA2PSEQvF2= NXTiN4pqW0GQR1XS
COLO-824 Ml:xS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFXoUnpKSzVyPUKuPFk4PjhizszN M1y5XXNCVkeHUh?=
ES1 M1zPUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXnJR|UxRTJwOEm4O|kh|ryP NICzXHNUSU6JRWK=
LB771-HNC NXftbXJbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYPJR|UxRTJwOUC5OFYh|ryP NETvcY1USU6JRWK=
GI-ME-N M4f0cmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4rDNGlEPTB;Mz6wNFkxPCEQvF2= MVPTRW5ITVJ?
NALM-6 Mo\oS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2n6c2lEPTB;Mz6wNFk{OyEQvF2= NIjCVFJUSU6JRWK=
LU-134-A NHHF[I9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVXJR|UxRTNwMEW0NlUh|ryP MWrTRW5ITVJ?
DMS-153 NYrL[GpjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUiyZmpJUUN3ME2zMlA2QDJ2IN88US=> M1;XZXNCVkeHUh?=
MZ1-PC MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYTVR|NxUUN3ME2zMlA6ODd6IN88US=> MnTZV2FPT0WU
NCI-H1155 NGLWbJpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1nZUWlEPTB;Mz6xNVYyKM7:TR?= M3PiUXNCVkeHUh?=
CAS-1 M3W1fmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoG4TWM2OD1|LkGzO|A4KM7:TR?= NWixcWxOW0GQR1XS
D-502MG M{PzWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYDoTZhFUUN3ME2zMlE1OzlizszN MW\TRW5ITVJ?
NCI-H2141 NUTOPFI4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUTKTFdNUUN3ME2zMlE4PDV{IN88US=> MWPTRW5ITVJ?
NB6 NYS5T29nT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmS0TWM2OD1|LkG4NlU6KM7:TR?= Mn\DV2FPT0WU
NCCIT MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkLGTWM2OD1|LkKxPFA6KM7:TR?= NFHXUVJUSU6JRWK=
NB69 NFm5No1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MonGTWM2OD1|LkOxPFkyKM7:TR?= NX31PGxGW0GQR1XS
JVM-2 M4HqU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXLBVoNuUUN3ME2zMlM3PDN|IN88US=> NVLoR5EyW0GQR1XS
K052 NYLqSYV{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVzZPVQ2UUN3ME2zMlM4QTZ6IN88US=> NFvPWWdUSU6JRWK=
HCC2157 M4\lbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXXJR|UxRTNwNUOyNlgh|ryP NWruc4xTW0GQR1XS
KMOE-2 NUm5V3o5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1XGW2lEPTB;Mz61OFI1OiEQvF2= NHTHdFhUSU6JRWK=
SF268 NGeyTWxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXPJR|UxRTNwN{G1OVQh|ryP NY\TU3poW0GQR1XS
CHP-126 NHXzcFFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUDJR|UxRTNwN{[0OVgh|ryP NXqxfGJoW0GQR1XS
CP66-MEL MoTTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWrRO3V5UUN3ME2zMlc6ODl2IN88US=> Ml7DV2FPT0WU
NCI-H69 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M13HfmlEPTB;ND6wNVk{PiEQvF2= MYHTRW5ITVJ?
A253 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXjH[GRyUUN3ME20MlAzOTBzIN88US=> NGfkSHdUSU6JRWK=
NB14 NHrwUlFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFvK[nlKSzVyPUSuNVA1PzlizszN MYXTRW5ITVJ?
NCI-H1694 NI\ncGRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYXJR|UxRTRwMUOxNVIh|ryP NUXBWGszW0GQR1XS
NCI-H2196 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3PKdWlEPTB;ND6xO|E3QSEQvF2= MV\TRW5ITVJ?
TE-9 M1S4XGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHvyWFNKSzVyPUSuNVc2QDJizszN MlW0V2FPT0WU
D-283MED NUXsRYlHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmrCTWM2OD12LkG4PFQh|ryP MorRV2FPT0WU
OCI-AML2 MonmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkDsTWM2OD12LkG5OFg6KM7:TR?= NGTSXG5USU6JRWK=
D-263MG MlfSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2Hsd2lEPTB;ND6yNlk3OSEQvF2= MUDTRW5ITVJ?
MPP-89 NYfGSHBDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkPzTWM2OD12LkK3N|A1KM7:TR?= M2fwfnNCVkeHUh?=
LAMA-84 NG\xNGFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWL0Xm1NUUN3ME20MlMxPDJzIN88US=> MoH3V2FPT0WU
LB373-MEL-D NHLjfnJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX[2eHRHUUN3ME20MlM3Pzh7IN88US=> NWHmfZd5W0GQR1XS
UACC-257 M4nEW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFLQTFFKSzVyPUSuN|k2OzRizszN M2S3S3NCVkeHUh?=
MC-CAR MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFj6SHJKSzVyPUSuOFM6QSEQvF2= M2CyS3NCVkeHUh?=
COLO-320-HSR Mnf1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mln0TWM2OD12LkS0OFI4KM7:TR?= M1vFe3NCVkeHUh?=
P30-OHK NH;yTpZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHTUVnZKSzVyPUSuOlY2QDFizszN NX7DZY1qW0GQR1XS
UACC-812 Mnu5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlnsTWM2OD12Lk[5NVYyKM7:TR?= MXfTRW5ITVJ?
CTB-1 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXzEPXlTUUN3ME20MlcyPTV3IN88US=> MnK2V2FPT0WU
ALL-PO NGXzUZVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkL1TWM2OD12Lki0NFc4KM7:TR?= NF3Sc3BUSU6JRWK=
SK-MEL-2 MlXuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnHITWM2OD12Lki2PVU2KM7:TR?= M{LzZ3NCVkeHUh?=
TC-YIK M2XDOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NE\0XJhKSzVyPUSuPVc6PDJizszN NIPzO4xUSU6JRWK=
NCI-H1882 Mnf4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MU\JR|UxRTVwMEKwNFEh|ryP MnS2V2FPT0WU
MHH-CALL-2 MnzqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWrOcVJxUUN3ME21MlA2ODR{IN88US=> NYjLNHRrW0GQR1XS
U-87-MG MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3LGVGlEPTB;NT6wPVQ3PiEQvF2= MYrTRW5ITVJ?
NCI-H1092 M2Hpdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWXJR|UxRTVwMk[1OVUh|ryP NES4PINUSU6JRWK=
TE-441-T NF\VdXFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXLJR|UxRTVwMke4NkDPxE1? Mn72V2FPT0WU
SK-MEL-1 MmS0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF\2O2tKSzVyPUWuNlkxPDRizszN NFTvRYRUSU6JRWK=
EW-22 M2S2cmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWXt[|VHUUN3ME21MlI6PDZ4IN88US=> M33TU3NCVkeHUh?=
MZ7-mel NHu3RlFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWja[lk4UUN3ME21MlQxPjlzIN88US=> NYnWd5U6W0GQR1XS
LP-1 M3rpfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIDw[YFKSzVyPUWuOFEzQTFizszN MV3TRW5ITVJ?
NCI-SNU-16 NXrsb3pvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEHzN|BKSzVyPUWuOlQxPzRizszN M{jnN3NCVkeHUh?=
LU-65 NGXzfnRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWTiPVl2UUN3ME21Mlc3Ozd|IN88US=> MUjTRW5ITVJ?
CW-2 NVLWSFhqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEfIbVZKSzVyPUWuPFU6PTlizszN MUTTRW5ITVJ?
WSU-NHL MoPRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NG\aNFhKSzVyPUWuPVUyPzRizszN NYrrbWdQW0GQR1XS
IST-MES1 NF\BOo1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYjJR|UxRTVwOUW0OFMh|ryP MYPTRW5ITVJ?
U-266 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFLLdnZKSzVyPUWuPVgzODJizszN M2\QR3NCVkeHUh?=
TALL-1 NVe3cGE1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIXyVHZKSzVyPU[uNVQ3QDhizszN MkDUV2FPT0WU
Calu-6 NGjGTnRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1nT[2lEPTB;Nj6xOVMyPiEQvF2= MWfTRW5ITVJ?
MMAC-SF NX62[4hST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYrJR|UxRTZwMUi1OVYh|ryP MUXTRW5ITVJ?
NCI-H82 M1TjXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1;6dGlEPTB;Nj6yNFQ5QSEQvF2= MoO1V2FPT0WU
RS4-11 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHXIUHdKSzVyPU[uNlU5QTdizszN MUDTRW5ITVJ?
SNU-C2B NGHxOpBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1rtd2lEPTB;Nj60NFk3QSEQvF2= NUj0cWRIW0GQR1XS
BOKU M3PB[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1\IdmlEPTB;Nj60O|U6PyEQvF2= MoXlV2FPT0WU
C8166 NXXWeHh3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M37YRWlEPTB;Nj61OVkyOiEQvF2= NETSc5pUSU6JRWK=
D-247MG MoDrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIfBR5dKSzVyPUeuNFQ{PDdizszN NVjNe4xUW0GQR1XS
EW-18 NYHkTGxsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXPJR|UxRTdwMEeyPVIh|ryP Ml3KV2FPT0WU
KG-1 MnrVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3nNemlEPTB;Nz62Nlc{QCEQvF2= NY\4bnZmW0GQR1XS
REH NIPDZ3VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkHQTWM2OD15Lk[4NVA6KM7:TR?= MXrTRW5ITVJ?
U-698-M MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mlr6TWM2OD15Lki0N|E2KM7:TR?= M3OwSHNCVkeHUh?=
KP-N-RT-BM-1 Mn\US5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYTDPWhGUUN3ME23Mlk{ODJ7IN88US=> NW\wNJlxW0GQR1XS
MS-1 NGiwcYFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWftelViUUN3ME23Mlk3ODRzIN88US=> M3jtbXNCVkeHUh?=
SNU-C1 NEXlbmVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEeySm1KSzVyPUeuPVgyQTJizszN M1f4b3NCVkeHUh?=
SK-MM-2 MlLhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1TkRmlEPTB;OD6yOlA3PSEQvF2= M1j5UnNCVkeHUh?=
LAN-6 MmroS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml7mTWM2OD16LkOwNFAyKM7:TR?= MmS1V2FPT0WU
NEC8 MkfFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUDJR|UxRThwM{C2PVEh|ryP NXGxSVhmW0GQR1XS
NCI-H1770 NF3nT2dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXHJR|UxRThwM{iwNFIh|ryP M135VXNCVkeHUh?=
D-336MG MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MljkTWM2OD16LkSwNVE3KM7:TR?= NXLrS5hTW0GQR1XS
COLO-829 MorlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnvhTWM2OD16LkS4PFc6KM7:TR?= Mn3jV2FPT0WU
LS-513 M4rDWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYjhN|NQUUN3ME24MlU6PTl7IN88US=> MVLTRW5ITVJ?
YT NV;1[FVvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUniU5ZnUUN3ME24MlYzPDJ5IN88US=> MXXTRW5ITVJ?
EW-24 MlrXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX\wO2VnUUN3ME24Mlc3PTRizszN M3\jSHNCVkeHUh?=
IST-SL1 M1XhdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4qzO2lEPTB;OD64OlU1OyEQvF2= NHzkUJFUSU6JRWK=
CA46 M1jNXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{jld2lEPTB;OD65OVA6QCEQvF2= MV7TRW5ITVJ?
NCI-H1838 NUjye4RwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2LkU2lEPTB;OD65PFYxOiEQvF2= NF7CeIFUSU6JRWK=
NCI-H719 NWDJfY57T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHfSVmNKSzVyPUmuNlUzPzlizszN MoHRV2FPT0WU
HCE-T MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1vWWWlEPTB;OT6zNFg2OSEQvF2= NVrUWHF2W0GQR1XS
A498 M17nWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXPPPHI3UUN3ME25MlM3OTJ2IN88US=> MWPTRW5ITVJ?
LB831-BLC NYTY[oo2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlzxTWM2OD17Lke2OVIyKM7:TR?= MVfTRW5ITVJ?
SKM-1 NVnFb|Y4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYTJR|UxRTlwOEW5OlMh|ryP NGrTfo9USU6JRWK=
THP-1 NXrY[XB3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV;JR|UxRTlwOU[5NVgh|ryP MWDTRW5ITVJ?
SHP-77 NEHud4JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXjJR|UxRTFyLkSwO{DPxE1? NVj4cGFiW0GQR1XS
EW-3 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWPJR|UxRTFyLk[yPFkh|ryP NY\SeGhXW0GQR1XS
KY821 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVTJR|UxRTFyLke2N{DPxE1? M{DhTnNCVkeHUh?=
NCI-SNU-1 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{K2NmlEPTB;MUGuNFIyPyEQvF2= M3u1W3NCVkeHUh?=
HCC2218 MlnES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoLRTWM2OD1zMT6zPVg3KM7:TR?= M2fpVnNCVkeHUh?=
IM-9 NHTGdG1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MY\JR|UxRTFzLkWxNFYh|ryP M2LHWnNCVkeHUh?=
NCI-H889 MoDjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUjzcFJRUUN3ME2xNU42OzF|IN88US=> NYr2clA1W0GQR1XS
HDLM-2 M2[zOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYPYR5FxUUN3ME2xNk41OTV7IN88US=> NGjiPWNUSU6JRWK=
LB2518-MEL NWW0dnZ1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoPKTWM2OD1zMj62PFE2KM7:TR?= MYHTRW5ITVJ?
NCI-H23 NETEVIpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGDLXGdKSzVyPUGzMlI1OjVizszN M4\LUXNCVkeHUh?=
NB17 M{H5UWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M16zSmlEPTB;MUOuOFU4QSEQvF2= NUTveIxvW0GQR1XS
NCI-H322M M2HoNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoOxTWM2OD1zND60NFY5KM7:TR?= M2TSXHNCVkeHUh?=
SUP-T1 NFXT[GtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1\UU2lEPTB;MUSuOFE{KM7:TR?= NYX4VGNxW0GQR1XS
ES3 NGnJNnBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWjldXZkUUN3ME2xOU4xPzB|IN88US=> MV;TRW5ITVJ?
ES5 NXHsVIZnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmXaTWM2OD1zNT6wO|g4KM7:TR?= NUXvSY5uW0GQR1XS
NCI-H1650 M{\sbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUT3bnJRUUN3ME2xOU41QTd7IN88US=> NWfLZYVVW0GQR1XS
NCI-H226 NID2dItIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoDkTWM2OD1zNT64O|Y5KM7:TR?= MXXTRW5ITVJ?
COR-L88 MnG3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1joeWlEPTB;MU[uN|E1KM7:TR?= NIPaemZUSU6JRWK=
SCC-15 M2rD[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUnJR|UxRTF4LkO4Olkh|ryP MlW4V2FPT0WU
GOTO NGG3N3RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVLJR|UxRTF4LkS3PVMh|ryP MnLiV2FPT0WU
SIMA M2i5Wmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFrQ[2tKSzVyPUG2MlQ5ODJizszN NFj0fFdUSU6JRWK=
NCI-H1299 NH64UW9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2PZN2lEPTB;MUeuNVU6OSEQvF2= M{fZS3NCVkeHUh?=
NCI-H1581 M2S0PGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{G5R2lEPTB;MUeuOFIyQSEQvF2= MUjTRW5ITVJ?
MHH-NB-11 M4jLWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmexTWM2OD1zNz65Olg{KM7:TR?= MV3TRW5ITVJ?
MFM-223 NX\ITYIzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NI\RblFKSzVyPUG4MlA2OzhizszN NXPxWGpUW0GQR1XS
ES7 NGD1PFlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHrBbppKSzVyPUG4MlU1OzFizszN MVzTRW5ITVJ?
JVM-3 NGTyWWVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NITnOYRKSzVyPUG4MlcyPyEQvF2= MnzWV2FPT0WU
RL MkTiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml7iTWM2OD1{MD6zPFgh|ryP MlPtV2FPT0WU
EC-GI-10 Mn34S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF61VnlKSzVyPUKxMlIxPDFizszN NWfGNGV6W0GQR1XS
LNCaP-Clone-FGC MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXPKSnk6UUN3ME2yNU43PzZ6IN88US=> MkK3V2FPT0WU
IMR-5 NWqxXGJ7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkLPTWM2OD1{MT64OFk1KM7:TR?= MnLYV2FPT0WU
KP-N-YS M{PieWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MU\JR|UxRTJzLki3OUDPxE1? MnH0V2FPT0WU
Mo-T NUXIPXptT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MU\JR|UxRTJ{LkKxPFUh|ryP NEjuV3pUSU6JRWK=
NCI-H128 M4D4ZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4\sZmlEPTB;MkOuOVg2OyEQvF2= NHKybHZUSU6JRWK=
RH-1 NVTRd5o2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3TifmlEPTB;MkOuO|g3PiEQvF2= M1e5N3NCVkeHUh?=
NCI-H2171 NWm1cHdtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVi2[3JWUUN3ME2yOE4zPDh3IN88US=> MXzTRW5ITVJ?
RPMI-8866 MnrUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVXqdIEyUUN3ME2yOk44PDJizszN MnnWV2FPT0WU
SK-N-FI MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHrn[pBKSzVyPUK3MlM5OTFizszN M4fNR3NCVkeHUh?=
LOXIMVI NVn3O5VkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVXJR|UxRTJ5LkiwOVEh|ryP NYfp[nk{W0GQR1XS
P31-FUJ MmXLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGTlN3RKSzVyPUOxMlU{PzRizszN NVvpXZB6W0GQR1XS
KMS-12-PE NX30cJdGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYLJR|UxRTR7LkWzNFIh|ryP NXruZXpjW0GQR1XS

... Click to View More Cell Line Experimental Data

In vivo Treatment with Rapamycin in vivo specifically blocks targets known to be downstream of mTOR such as the phosphorylation and activation of p70S6K and the release of inhibition of eIF4E by PHAS-1/4E-BP1, leading to complete blockage of the hypertrophic increases in plantaris muscle weight and fibre size. [4] Short-term Rapamycin treatment, even at the lowest dose of 0.16 mg/kg, produces profound inhibition of p70S6K activity, which correlates with increased tumor cell death and necrosis of the Eker renal tumors. [5] Rapamycin inhibits metastatic tumor growth and angiogenesis in CT-26 xenograft models by reducing the production of VEGF and blockage of VEGF-induced endothelial cell signaling. [6] Rapamycin treatment at 4 mg/kg/day significantly reduces tumor growth of C6 xenografts, and tumor vascular permeability. [7]

Protocol

Kinase Assay:

[1]

+ Expand

Immunoblotting for the mTOR kinase assay:

HEK293 cells are plated at 2-2.5×105 cells/well of a 12-well plate and serum-starved for 24 hours in DMEM. Cells are treated with increasing concentrations of Rapamycin (0.05-50 nM) for 15 minutes at 37 °C. Serum is added to a final concentration of 20% for 30 minutes at 37 °C. Cells are lysed, and cell lysates are separated by SDS-PAGE. Resolved proteins are transferred to a polyvinylidene difluoride membrane and immunoblotted with a phosphospecific primary antibody against Thr-389 of p70 S6 kinase. Data are analyzed using ImageQuant and KaleidaGr
Cell Research:

[3]

+ Expand
  • Cell lines: U87-MG, T98G, and U373-MG
  • Concentrations: Dissolved in DMSO, final concentrations ~25 μM
  • Incubation Time: 72 hours
  • Method:

    Cells are exposed to various concentrations of Rapamycin for 72 hours. For the assessment of cell viability, cells are collected by trypsinization, stained with trypan blue, and the viable cells in each well are counted. For the determination of cell cycle, cells are trypsinized, fixed with 70% ethanol, and stained with propidium iodide using a flow cytometry reagent set. Samples are analyzed for DNA content using a FACScan flow cytometer and CellQuest software. For apoptosis detection, cells are stained with the terminal deoxynucleotidyl transferase-mediated dUTP nick end labeling (TUNEL) technique using an ApopTag apoptosis detection kit. To detect the development of acidic vesicular organelles (AVO), cells are stained with acridine orange (1 μg/mL) for 15 minutes, and examined under a fluorescence microscope. To quantify the development of AVOs, cells are stained with acridine orange (1 μg/mL) for 15 minutes, removed from the plate with trypsin-EDTA, and analyzed using the FACScan flow cytometer and CellQuest software. To analyze the autophagic process, cells are incubated for 10 minutes with 0.05 mM monodansylcadaverine at 37 °C and are then observed under a fluorescence microscope.


    (Only for Reference)
Animal Research:

[7]

+ Expand
  • Animal Models: Athymic Nu/Nu mice inoculated subcutaneously with VEGF-A-expressing C6 rat glioma cells
  • Formulation: Dissolved in solvent solution (0.2% carboxymethylcellulose and 0.25% Tween-80 in sterile H2O)
  • Dosages: ~4 mg/kg/day
  • Administration: Injection i.p.
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 20 mg/mL (21.87 mM)
Water slightly soluble or insoluble
Ethanol slightly soluble or insoluble
In vivo Add solvents individually and in order:
2% DMSO+30% PEG 300+5% Tween 80+ddH2O
5mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 914.18
Formula

C51H79NO13

CAS No. 53123-88-9
Storage powder
in solvent
Synonyms AY 22989,NSC-2260804

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT00062712 Completed Kidney Transplantation National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|National Institutes of Health Clinical Center (CC) June 9, 2003 Phase 2
NCT01814059 Terminated Eosinophilic Gastroenteritis|Eosinophilic Esophagitis National Institute of Allergy and Infectious Diseases (NIAID)|National Institutes of Health Clinical Center (CC) March 7, 2013 Phase 1
NCT01303965 Active, not recruiting Multiple Myeloma Sherif S. Farag|Celgene Corporation|Indiana University February 7, 2011 Phase 1|Phase 2
NCT02891603 Not yet recruiting Graft Vs Host Disease|GVHD H. Lee Moffitt Cancer Center and Research Institute April 30, 2017 Phase 1|Phase 2
NCT02423915 Recruiting Leukemia|Lymphoma M.D. Anderson Cancer Center|National Cancer Institute (NCI)|Targazyme, Inc.|Cancer Prevention Research Institute of Texas July 30, 2015 Phase 1|Phase 2
NCT01182883 Withdrawn Brain Stem Neoplasms|Glioma|Pinealoma National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) July 28, 2010 Phase 1

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

mTOR Signaling Pathway Map

mTOR Inhibitors with Unique Features

Related mTOR Products

Tags: buy Rapamycin (Sirolimus) | Rapamycin (Sirolimus) supplier | purchase Rapamycin (Sirolimus) | Rapamycin (Sirolimus) cost | Rapamycin (Sirolimus) manufacturer | order Rapamycin (Sirolimus) | Rapamycin (Sirolimus) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID